Why the study?
Cardiovascular risk remains elevated for at least 12 months after COVID-19 infection, highlighting the need to understand endothelial dysfunction across disease severity, recovery, and therapeutic targets.
Answers are grounded in this paper and cite their sources.
This review highlights the prolonged cardiovascular risk following COVID-19 infection driven by endothelial dysfunction and identifies gaps for future therapeutic research.
Endothelial dysfunction represents a measurable and early manifestation of vascular disease. Emerging evidence suggests cardiovascular risk remains elevated after COVID-19 infection for at least 12 months, regardless of cardiovascular disease status prior to infection. We review the relationship between the severity of endothelial dysfunction and the severity of acute COVID-19 illness, the degree of impairment following recovery in both those with and without postacute sequalae SARS-CoV-2 infection, and current therapeutic efforts targeting endothelial function in patients following COVID-19 infection. We identify gaps in the literature to highlight specific areas where clinical research efforts hold promise for progress in understanding the connections between endothelial function, COVID-19, and clinical outcomes that will lead to beneficial therapeutics.
No takes yet. Share an insight, caveat, or question.
Aljadah et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: